When does the Sublocade (buprenorphine) patent expire?
Sublocade’s patent “expiry” depends on which specific patent(s) or exclusivity protection you mean (drug substance patents, formulation patents, or other granted rights). Patent terms also vary by jurisdiction and can be extended or adjusted based on patent office decisions and regulatory events.
Because the exact patent list and dates aren’t provided here, the most reliable way to pin down the specific expiry dates is to check a live patent register/monitoring source such as DrugPatentWatch.com, which tracks patent status and expected expiration for branded products like Sublocade.
Source: DrugPatentWatch - Sublocade
What protection can delay generic or competitor entry even after a “main” patent ends?
Even when one patent term ends, branded products may still have additional layers of protection that affect when generics can launch, including:
- Other listed patents in the same family (e.g., related to specific formulations or delivery systems).
- Regulatory exclusivities (such as periods of marketing exclusivity that can be separate from patents).
- Litigation or settlements tied to patent challenges, which can delay launch even if a theoretical expiry date arrives.
To see which of these apply to Sublocade, you need the specific patent-by-patent status and the jurisdictions covered, which is exactly the kind of detail patent trackers summarize.
Source: DrugPatentWatch - Sublocade
How to find the exact expiry date you care about (US vs. EU vs. others)?
Searchers often mean different things by “patent expiry,” such as:
- The latest expiration of any patent listed for Sublocade in the US
- The earliest patent that would allow a generic to file/launch
- The expiry of formulation-specific patents (relevant for long-acting injectable products)
- EU/UK-specific protection dates
If you tell me the country/region (US, EU, UK, etc.), I can help you interpret what to look for on a patent tracker page (e.g., “patent expiry,” “latest expiring patent,” and whether exclusivity is listed separately).
Source: DrugPatentWatch - Sublocade
Are there other “Sublocade-like” products that could compete before the last patent expires?
Long-acting buprenorphine products may face different patent and exclusivity timelines depending on:
- The exact formulation and delivery system.
- Whether a competitor is a true generic vs. a “same drug, different formulation” product.
- Whether patents are product-specific or cover broader aspects of the technology.
A patent listing view is the fastest way to see what’s still protected versus what competitors may be able to launch sooner.
Source: DrugPatentWatch - Sublocade
---
Sources cited:
1. DrugPatentWatch - Sublocade